148 related articles for article (PubMed ID: 9345018)
1. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome.
List AF; Brasfield F; Heaton R; Glinsmann-Gibson B; Crook L; Taetle R; Capizzi R
Blood; 1997 Nov; 90(9):3364-9. PubMed ID: 9345018
[TBL] [Abstract][Full Text] [Related]
2. Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels.
Hofmann WK; Seipelt G; Ottmann OG; Kalina U; Koschmieder S; Brücher J; Frickhofen N; Klausmann M; Mitrou PS; Hoelzer D
Ann Hematol; 2000 May; 79(5):255-8. PubMed ID: 10870480
[TBL] [Abstract][Full Text] [Related]
3. Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome.
Neumeister P; Jaeger G; Eibl M; Sormann S; Zinke W; Linkesch W
Leuk Lymphoma; 2001 Jan; 40(3-4):345-9. PubMed ID: 11426556
[TBL] [Abstract][Full Text] [Related]
4. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
5. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.
Silverman LR; Holland JF; Weinberg RS; Alter BP; Davis RB; Ellison RR; Demakos EP; Cornell CJ; Carey RW; Schiffer C
Leukemia; 1993 May; 7 Suppl 1():21-9. PubMed ID: 7683352
[TBL] [Abstract][Full Text] [Related]
6. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Raza A; Qawi H; Lisak L; Andric T; Dar S; Andrews C; Venugopal P; Gezer S; Gregory S; Loew J; Robin E; Rifkin S; Hsu WT; Huang RW
Blood; 2000 Mar; 95(5):1580-7. PubMed ID: 10688811
[TBL] [Abstract][Full Text] [Related]
7. Amifostine in the treatment of low-risk myelodysplastic syndromes.
Grossi A; Fabbri A; Santini V; Leoni F; Nozzoli C; Longo G; Pagliai G; Ciolli S; Rossi Ferrini P
Haematologica; 2000 Apr; 85(4):367-71. PubMed ID: 10756361
[TBL] [Abstract][Full Text] [Related]
8. Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome.
Yilmaz A; Kaufmann CC; Binder C; Wörmann B; Haase D
Ann Hematol; 2001 Jan; 80(1):53-7. PubMed ID: 11233778
[TBL] [Abstract][Full Text] [Related]
9. Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Erikci AA; Ozturk A; Karagoz B; Bilgi O; Turken O; Top C; Kandemir EG
Hematology; 2008 Oct; 13(5):289-92. PubMed ID: 18854092
[TBL] [Abstract][Full Text] [Related]
10. Use of amifostine in hematologic malignancies, myelodysplastic syndrome, and acute leukemia.
List AF
Semin Oncol; 1999 Apr; 26(2 Suppl 7):61-5. PubMed ID: 10348262
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with myelodysplastic syndrome with amifostine.
Galanopoulos A; Kritikou-Griva E; Gligori J; Michalis E; Grigoraki V; Marinakis T; Kakkas J; Tasiopoulou A; Anagnostopoulos NI
Leuk Res; 2001 Aug; 25(8):665-71. PubMed ID: 11397471
[TBL] [Abstract][Full Text] [Related]
12. Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia.
van Kamp H; Prinsze-Postema TC; Kluin PM; den Ottolander GJ; Beverstock GC; Willemze R; Fibbe WE
Br J Haematol; 1991 Aug; 78(4):488-93. PubMed ID: 1911340
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes.
Invernizzi R; Pecci A; Travaglino E; Gobbi PG; Malabarba L; Ramajoli I; Ascari E
Br J Haematol; 2002 Jul; 118(1):246-50. PubMed ID: 12100155
[TBL] [Abstract][Full Text] [Related]
14. Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Tsiara SN; Kapsali HD; Panteli K; Christou L; Bourantas KL
J Exp Clin Cancer Res; 2001 Mar; 20(1):35-8. PubMed ID: 11370827
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
[TBL] [Abstract][Full Text] [Related]
16. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
17. Amifostine treatment in patients with myelodysplastic syndrome.
Çetiner M; Fıratlı Tuğlular T; Özen Al Ahdab Y; Al Ahdab H; Köse M; Noyan F; Adıgüzel C; Ovalı E; Bayık M
Turk J Haematol; 2005 Sep; 22(3):117-23. PubMed ID: 27264833
[TBL] [Abstract][Full Text] [Related]
18. [Application of bioinformatics analysis to optimize amifostine combination therapeutic regimen of myelodysplastic syndrome].
Lu XC; Yang B; Zhu HL; Fan H; Li SX; Liu Y; Yao SQ
Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(26):1834-7. PubMed ID: 19953928
[TBL] [Abstract][Full Text] [Related]
19. Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF.
Nagler A; Binet C; Mackichan ML; Negrin R; Bangs C; Donlon T; Greenberg P
Blood; 1990 Oct; 76(7):1299-307. PubMed ID: 1698477
[TBL] [Abstract][Full Text] [Related]
20. Dosing considerations with amifostine: a review of the literature and clinical experience.
Dorr RT; Holmes BC
Semin Oncol; 1999 Apr; 26(2 Suppl 7):108-19. PubMed ID: 10348269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
